Valsartan

membrane metalloendopeptidase ; Homo sapiens







127 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35050813 Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. 2022 Feb 1
2 35253964 Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension. 2022 Apr 1
3 35343479 [Sacubitril/valsartan in oncologic patients with cardiotoxicity: another weapon in our pharmacological armory?] 2022 Apr 1
4 35469709 Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. 2022 Apr 22 2
5 33148948 TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. 2021 Jan 1
6 33189632 Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 2021 Feb 1
7 33422508 Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening! 2021 Mar 5 1
8 33459776 Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. 2021 Feb 11 1
9 33732669 Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy. 2021 1
10 33808232 Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF. 2021 Mar 30 1
11 33822031 Renal protection in chronic heart failure: focus on sacubitril/valsartan. 2021 Sep 21 1
12 33989294 Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction? 2021 1
13 34173810 Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan. 2021 Sep 1 1
14 34216577 Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application. 2021 Sep 15 1
15 34273070 Current and emerging drug targets in heart failure treatment. 2021 Jul 17 1
16 34612065 Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. 2021 Oct 19 1
17 34703936 Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure. 2021 Oct 8 1
18 34859070 Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. 2021 1
19 30776953 Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia. 2020 Oct 1
20 30991886 Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report. 2020 Aug 1
21 31028383 Chronic kidney disease, heart failure and neprilysin inhibition. 2020 Apr 1 1
22 31392960 Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 2020 Jan 1
23 32319309 ARNI in cardiovascular disease: current evidence and future perspectives. 2020 Sep 1
24 32336521 When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry. 2020 Mar 1
25 32348960 Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. 2020 May 1
26 32352509 Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan). 2020 Jul 1 1
27 32370992 Response to the Letter to the Editor "When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry". 2020 Mar 1
28 32490351 Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports. 2020 1
29 32648251 Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure. 2020 1
30 32653447 Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. 2020 Oct 1
31 32710603 Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure. 2020 Oct 1
32 32744827 Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration? 2020 Sep 1
33 32848403 Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data. 2020 1
34 32987038 Neprilysin expression and functions in development, ageing and disease. 2020 Dec 2
35 32995716 Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. 2020 Sep 1
36 33004114 Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. 2020 Oct 1
37 33032741 Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. 2020 Oct 13 1
38 33203141 The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. 2020 Nov 15 1
39 33224383 Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. 2020 Dec 1
40 33489085 Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. 2020 1
41 33727901 The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. 2020 Nov 1
42 29450561 Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study. 2019 Sep 2
43 29635392 Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients? 2019 Jan 1 1
44 29891240 Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. 2019 Apr 15 1
45 29926350 Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. 2019 Feb 1
46 30420146 Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. 2019 Apr 15 1
47 30520545 Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. 2019 May 4
48 30679005 Sacubitril/valsartan: A practical guide. 2019 May 1
49 30712431 Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 2019 Feb 5 1
50 30895809 Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35. 2019 May 1